Warren B, Munoz-Schuffenegger P, Chan K K W, Chu W, Helou J, Erler D, Chung H
Department of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Medical Oncology, University of Toronto, Toronto, Ontario, Canada; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada; Department of Hematology - Oncology, Faculty of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile.
Clin Oncol (R Coll Radiol). 2017 Sep;29(9):e141-e147. doi: 10.1016/j.clon.2017.03.011. Epub 2017 Apr 12.
Stereotactic body radiation therapy (SBRT) is increasingly used as an option for those with liver metastases. In order to facilitate future economic impact of health technologies, health utility scores may be used. The EuroQOL-5D-3L (EQ-5D) preference-based healthy utility instrument was used to evaluate the impact of treatment with SBRT on health utility scores.
Between August 2013 and October 2014, 31 patients treated with 3-5 fractions of SBRT for liver metastases were enrolled in this study. The EQ-5D instrument was administered at baseline, during and up to 6 months post-SBRT.
Mean EQ-5D score at baseline was 0.857, which remained stable across the entire study time period. Transient increases in difficulties with mobility (9.7% reported at baseline to 16.1% on the last day of treatment) and usual activities (3.2% reported at baseline to 34.5% on day two) were found during the course of treatment; these returned to baseline levels subsequently. The mean visual analogue score at baseline was 65.8 and remained unchanged throughout treatment and follow-up.
The stability of health utility scores and problems reported by patients undergoing treatment indicate that SBRT for liver metastases does not impart a significant adverse effect on quality of life. These results may be used for future economic evaluation of SBRT.
立体定向体部放射治疗（SBRT）越来越多地被用作肝转移患者的一种治疗选择。为了促进未来卫生技术的经济影响评估，可使用健康效用评分。基于偏好的健康效用工具欧洲五维健康量表（EQ-5D）用于评估SBRT治疗对健康效用评分的影响。
2013年8月至2014年10月，本研究纳入了31例接受3 - 5次分割SBRT治疗肝转移的患者。EQ-5D工具在基线、SBRT治疗期间及治疗后长达6个月时进行应用。
基线时EQ-5D平均评分为0.857，在整个研究时间段内保持稳定。在治疗过程中发现，行动能力困难（基线时报告为9.7%，治疗最后一天为16.1%）和日常活动困难（基线时报告为3.2%，第2天为34.5%）出现短暂增加；随后这些情况恢复到基线水平。基线时视觉模拟评分平均为65.8，在整个治疗和随访过程中保持不变。
接受治疗患者的健康效用评分稳定性以及所报告的问题表明，SBRT治疗肝转移对生活质量没有显著不良影响。这些结果可用于未来SBRT的经济评估。
